@article{
 title = {Open label evaluation of cannabidiol in dystonic movement disorders.},
 type = {article},
 year = {1986},
 identifiers = {[object Object]},
 keywords = {Adult,Aged,Cannabidiol,Cannabidiol: adverse effects,Cannabidiol: therapeutic use,Cannabinoids,Cannabinoids: therapeutic use,Dystonia,Dystonia Musculorum Deformans,Dystonia Musculorum Deformans: drug therapy,Dystonia: chemically induced,Dystonia: drug therapy,Female,Humans,Levodopa,Levodopa: adverse effects,Male,Meige Syndrome,Meige Syndrome: drug therapy,Middle Aged,Muscle Spasticity,Muscle Spasticity: drug therapy,Torticollis,Torticollis: drug therapy},
 pages = {277-82},
 volume = {30},
 websites = {http://www.ncbi.nlm.nih.gov/pubmed/3793381},
 id = {ff909143-165d-3a8c-a7a1-c6c889f2579c},
 created = {2017-04-04T03:53:44.065Z},
 file_attached = {true},
 profile_id = {32112794-3515-31de-a0a8-eabadccd1b7c},
 group_id = {4cb6f261-be0d-3474-9ccf-7abee0d15aec},
 last_modified = {2017-04-04T03:54:14.413Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 folder_uuids = {9720b478-a6c5-4fdb-9225-b10f28aec909},
 private_publication = {false},
 abstract = {Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.},
 bibtype = {article},
 author = {Consroe, P and Sandyk, R and Snider, S R},
 journal = {The International journal of neuroscience},
 number = {4}
}

{"_id":"t24cPQ7oboETsBsH2","bibbaseid":"consroe-sandyk-snider-openlabelevaluationofcannabidiolindystonicmovementdisorders-1986","downloads":0,"creationDate":"2017-12-17T23:25:46.783Z","title":"Open label evaluation of cannabidiol in dystonic movement disorders.","author_short":["Consroe, P.","Sandyk, R.","Snider, S., R."],"year":1986,"bibtype":"article","biburl":null,"bibdata":{"title":"Open label evaluation of cannabidiol in dystonic movement disorders.","type":"article","year":"1986","identifiers":"[object Object]","keywords":"Adult,Aged,Cannabidiol,Cannabidiol: adverse effects,Cannabidiol: therapeutic use,Cannabinoids,Cannabinoids: therapeutic use,Dystonia,Dystonia Musculorum Deformans,Dystonia Musculorum Deformans: drug therapy,Dystonia: chemically induced,Dystonia: drug therapy,Female,Humans,Levodopa,Levodopa: adverse effects,Male,Meige Syndrome,Meige Syndrome: drug therapy,Middle Aged,Muscle Spasticity,Muscle Spasticity: drug therapy,Torticollis,Torticollis: drug therapy","pages":"277-82","volume":"30","websites":"http://www.ncbi.nlm.nih.gov/pubmed/3793381","id":"ff909143-165d-3a8c-a7a1-c6c889f2579c","created":"2017-04-04T03:53:44.065Z","file_attached":"true","profile_id":"32112794-3515-31de-a0a8-eabadccd1b7c","group_id":"4cb6f261-be0d-3474-9ccf-7abee0d15aec","last_modified":"2017-04-04T03:54:14.413Z","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"folder_uuids":"9720b478-a6c5-4fdb-9225-b10f28aec909","private_publication":false,"abstract":"Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.","bibtype":"article","author":"Consroe, P and Sandyk, R and Snider, S R","journal":"The International journal of neuroscience","number":"4","bibtex":"@article{\n title = {Open label evaluation of cannabidiol in dystonic movement disorders.},\n type = {article},\n year = {1986},\n identifiers = {[object Object]},\n keywords = {Adult,Aged,Cannabidiol,Cannabidiol: adverse effects,Cannabidiol: therapeutic use,Cannabinoids,Cannabinoids: therapeutic use,Dystonia,Dystonia Musculorum Deformans,Dystonia Musculorum Deformans: drug therapy,Dystonia: chemically induced,Dystonia: drug therapy,Female,Humans,Levodopa,Levodopa: adverse effects,Male,Meige Syndrome,Meige Syndrome: drug therapy,Middle Aged,Muscle Spasticity,Muscle Spasticity: drug therapy,Torticollis,Torticollis: drug therapy},\n pages = {277-82},\n volume = {30},\n websites = {http://www.ncbi.nlm.nih.gov/pubmed/3793381},\n id = {ff909143-165d-3a8c-a7a1-c6c889f2579c},\n created = {2017-04-04T03:53:44.065Z},\n file_attached = {true},\n profile_id = {32112794-3515-31de-a0a8-eabadccd1b7c},\n group_id = {4cb6f261-be0d-3474-9ccf-7abee0d15aec},\n last_modified = {2017-04-04T03:54:14.413Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n folder_uuids = {9720b478-a6c5-4fdb-9225-b10f28aec909},\n private_publication = {false},\n abstract = {Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.},\n bibtype = {article},\n author = {Consroe, P and Sandyk, R and Snider, S R},\n journal = {The International journal of neuroscience},\n number = {4}\n}","author_short":["Consroe, P.","Sandyk, R.","Snider, S., R."],"urls":{"Paper":"http://bibbase.org/service/mendeley/6c9edcaf-81dc-3357-bb56-dee7616baa0c/file/6c2c66f8-e38c-39cd-1d19-8020bc03cf7c/1986-Open_label_evaluation_of_cannabidiol_in_dystonic_movement_disorders..pdf.pdf","Website":"http://www.ncbi.nlm.nih.gov/pubmed/3793381"},"bibbaseid":"consroe-sandyk-snider-openlabelevaluationofcannabidiolindystonicmovementdisorders-1986","role":"author","keyword":["Adult","Aged","Cannabidiol","Cannabidiol: adverse effects","Cannabidiol: therapeutic use","Cannabinoids","Cannabinoids: therapeutic use","Dystonia","Dystonia Musculorum Deformans","Dystonia Musculorum Deformans: drug therapy","Dystonia: chemically induced","Dystonia: drug therapy","Female","Humans","Levodopa","Levodopa: adverse effects","Male","Meige Syndrome","Meige Syndrome: drug therapy","Middle Aged","Muscle Spasticity","Muscle Spasticity: drug therapy","Torticollis","Torticollis: drug therapy"],"downloads":0},"search_terms":["open","label","evaluation","cannabidiol","dystonic","movement","disorders","consroe","sandyk","snider"],"keywords":["adult","aged","cannabidiol","cannabidiol: adverse effects","cannabidiol: therapeutic use","cannabinoids","cannabinoids: therapeutic use","dystonia","dystonia musculorum deformans","dystonia musculorum deformans: drug therapy","dystonia: chemically induced","dystonia: drug therapy","female","humans","levodopa","levodopa: adverse effects","male","meige syndrome","meige syndrome: drug therapy","middle aged","muscle spasticity","muscle spasticity: drug therapy","torticollis","torticollis: drug therapy"],"authorIDs":[]}